Ataraxis AI is at the forefront of transforming cancer care through its innovative AI Precision Medicine technology. The company focuses on developing advanced artificial intelligence methods that integrate multi-modal data, allowing for a comprehensive understanding of cancer prognosis and treatment selection. By utilizing AI foundation models, such as Kestrel, which are trained on extensive datasets of pathology images, Ataraxis can uncover critical clinical, morphological, and molecular features that reflect the complexity of cancer. This multi-faceted approach enables the identification of patient-specific characteristics that are crucial for tailoring treatment plans, ultimately improving patient outcomes.

The proprietary technology of Ataraxis AI also emphasizes rapid and efficient analysis, with results delivered within an unprecedented timeframe of one hour. This capability is particularly significant as it allows for timely decision-making in clinical settings without the need for additional tissue preparation. Ataraxis Breast, the company's flagship product, has demonstrated superior predictive accuracy compared to standard genomic assays, effectively identifying high- and low-risk patients across various breast cancer subtypes. The platform's robust and extensible nature ensures that it can adapt to new clinical questions, making it a valuable tool in precision oncology for diverse patient populations.

United States

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data.

Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

Ataraxis AI

Company Details